ACCESS Newswire

MicroVision, Inc.

9.5.2023 23:02:10 CEST | ACCESS Newswire | Press release

Share
MicroVision Announces First Quarter 2023 Results

REDMOND, WA / ACCESSWIRE / May 9, 2023 / MicroVision, Inc. (NASDAQ:MVIS), a leader in MEMS-based solid-state automotive lidar and ADAS solutions, today announced its first quarter 2023 results.

"Following the closing in January of our acquisition of assets from Ibeo Automotive Systems GmbH, we are energized by the strength of our combined team, accelerated engagement with multiple OEMs, and positive financial performance in Q1 2023. Revenue of $0.8 million was ahead of our expectations, primarily driven by the acquisition." said Sumit Sharma, MicroVision's Chief Executive Officer. "I am pleased with our significant achievements in the first quarter, with the momentum in our top line driven by our expanded product offerings and the efficient integration of our U.S. and Germany teams.

"With the dynamic-view MAVIN™, our MEMS-based scanning lidar for long-range highway pilot; MOVIA™, our flash-based short-range lidar for automotive and non-automotive applications; and MOSAIK™, our validation software suite for OEMs and Tier 1s, MicroVision is uniquely positioned to capture meaningful market share in both automotive and non-automotive verticals," continued Sharma. "Our product offerings and unmatched technical capabilities are proving to be compelling in key RFIs and RFQs from several OEMs around the globe. We maintain our 2023 revenue guidance of $10-15 million from our expanded product suite."

Key Financial Highlights for Q1 2023

  • Revenue for the first quarter of 2023 was $0.8 million, compared to $0.4 million for the first quarter of 2022. The revenue growth in the first quarter was primarily due to the IBEO acquisition and includes the sale of lidar hardware and related software to various customers.
  • Net loss for the first quarter of 2023 was $19.0 million, or $0.11 per share, which includes $2.9 million of non-cash, share-based compensation expense, $1.7 million bargain purchase price gain, compared to a net loss for the first quarter of 2022 of $13.2 million, or $0.08 per share, which includes $3.7 million of non-cash, share-based compensation expense.
  • Adjusted Gross Profit for the first quarter of 2023 was a $0.5 million, compared to a $0.3 million for the first quarter of 2022.
  • Adjusted EBITDA for the first quarter of 2023 was a $15.8 million loss, compared to a $9.0 million loss for the first quarter of 2022.
  • Cash used in operations in the first quarter of 2023 was $13.8 million, compared to cash used in operations in the first quarter of 2022 of $10.9 million.
  • The Company ended the first quarter of 2023 with $67.7 million in cash and cash equivalents including investment securities, compared to $82.7 million at December 31, 2022.

Conference Call and Webcast: Q1 2023 Results

MicroVision will host a conference call and webcast, consisting of prepared remarks by management, a slide presentation, and a question-and-answer session at 2:00 PM PT/5:00 PM ET on Tuesday, May 9, 2023 to discuss the financial results and provide a business update. Analysts and investors may pose questions to management during the live webcast on May 9, 2023.

The live webcast and slide presentation can be accessed on the Company's Investor Relations website under the Events tab at https://ir.microvision.com/events. The webcast will be archived on the website for future viewing.

About MicroVision

With over 350 employees and global presence in Redmond, Detroit, Hamburg, and Nuremberg, MicroVision is a pioneering company in MEMS-based laser beam scanning technology that integrates MEMS, lasers, optics, hardware, algorithms and machine learning software into its proprietary technology to address existing and emerging markets. The Company's integrated approach uses its proprietary technology to provide automotive lidar sensors and solutions for advanced driver-assistance systems (ADAS) and for non-automotive applications including industrial, smart infrastructure and robotics. The Company has been leveraging its experience building augmented reality micro-display engines, interactive display modules, and consumer lidar modules.

For more information, visit the Company's website at www.microvision.com, on Facebook at www.facebook.com/microvisioninc, and LinkedIn at https://www.linkedin.com/company/microvision/.

MicroVision, MAVIN, MOSAIK, and MOVIA are trademarks of MicroVision, Inc. in the United States and other countries. All other trademarks are the properties of their respective owners.

Non-GAAP information

To supplement MicroVision's condensed financial statements presented in accordance with GAAP, the Company presents investors with the non-GAAP financial measure "adjusted EBITDA" and "adjusted Gross Profit." Adjusted EBITDA consists of GAAP net income (loss) excluding the impact of the following: interest income and interest expense; income tax expense; depreciation and amortization; and share-based compensation. Adjusted Gross Profit is calculated as GAAP gross profit before stock-based compensation expense and the amortization of acquired intangibles included in cost of revenue.

MicroVision believes that the presentation of adjusted EBITDA and adjusted Gross Profit provides important supplemental information to management and investors regarding financial and business trends, provides consistency and comparability with MicroVision's past financial reports, and facilitates comparisons with other companies in the Company's industry, many of which use similar non-GAAP financial measures to supplement their GAAP results. Internally, management uses this non-GAAP measure when evaluating operating performance because the exclusion of the items described above provides an additional useful measure of the Company's operating results and facilitates comparisons of the Company's core operating performance against prior periods and its business objectives. Externally, the Company believes that adjusted EBITDA and adjusted Gross Profit is useful to investors in their assessment of MicroVision's operating performance and the valuation of the Company.

Adjusted EBITDA and adjusted Gross Profit is not calculated in accordance with GAAP, and should be considered supplemental to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. Non-GAAP financial measures have limitations in that they do not reflect all of the costs associated with the operations of MicroVision's business as determined in accordance with GAAP. The Company expects to continue to incur expenses similar to the non-GAAP adjustments described above, and exclusion of these items from its non-GAAP financial measure should not be construed as an inference that these costs are unusual or infrequent. The Company compensates for limitations of the measure by prominently disclosing GAAP net income (loss), which the Company believes is the most directly comparable GAAP measure, and providing investors with a reconciliation from GAAP net income (loss) to adjusted EBITDA.

Similarly for Adjusted Gross Profit, the Company compensates for limitations of the measure by prominently disclosing GAAP gross profits which is the difference between Revenue and Cost of revenue, which the Company believes is the most directly comparable GAAP measure, and providing investors with a reconciliation by backing out stock-based compensation expense and the amortization of acquired intangibles included in cost of revenue.

Forward-Looking Statements

Certain statements contained in this release, including the Company's plans regarding benefits of the acquisition, market position, product portfolio, product capabilities, and expected revenue, expenses and cash usage are forward-looking statements that involve a number of risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those projected in such forward-looking statements include the risk its ability to operate with limited cash or to raise additional capital when needed; market acceptance of its technologies and products or for products incorporating its technologies; the failure of its commercial partners to perform as expected under its agreements, including from the impact of COVID-19 (coronavirus); its financial and technical resources relative to those of its competitors; its ability to keep up with rapid technological change; government regulation of its technologies; its ability to enforce its intellectual property rights and protect its proprietary technologies; the ability to obtain customers and develop partnership opportunities; the timing of commercial product launches and delays in product development; the ability to achieve key technical milestones in key products; dependence on third parties to develop, manufacture, sell and market its products; potential product liability claims; its ability to maintain its listing on The Nasdaq Stock Market, and other risk factors identified from time to time in the Company's SEC reports, including the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other reports filed with the SEC. These factors are not intended to represent a complete list of the general or specific factors that may affect the Company. It should be recognized that other factors, including general economic factors and business strategies, may be significant, now or in the future, and the factors set forth in this release may affect the Company to a greater extent than indicated. Except as expressly required by federal securities laws, the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changes in circumstances or any other reason.

Investor Relations Contact
Jeff Christensen
Darrow Associates Investor Relations
MVIS@darrowir.com

Media Contact
Robyn Komachi
Marketing@MicroVision.com

MicroVision, Inc.
Consolidated Balance Sheet
(In thousands)
(Unaudited)


March 31, December 31,

2023 2022



Assets


Current Assets


Cash and cash equivalents
$23,187 $20,536
Investment securities, available-for-sale
44,544 62,173
Restricted cash, current
3,263 -
Accounts receivable, net
506 -
Contract assets
192 -
Inventory
3,116 1,861
Advance to IBEO
- 4,132
Other current assets
2,182 2,306
Total current assets
76,990 91,008

Property and equipment, net
10,284 6,830
Operating lease right-of-use asset
14,746 14,579
Restricted cash
961 1,418
Intangible assets, net
19,000 75
Other assets
1,281 1,086
Total assets
$123,262 $114,996


Liabilities and Shareholders' Equity
Current Liabilities
Accounts payable
$3,629 $2,061
Accrued liabilities
10,414 2,058
Contract liabilities
5,676 4,601
Other current liabilities
211 839
Current portion of operating lease liability
2,210 1,846
Current portion of finance lease obligations
15 21
Total current liabilities
22,155 11,426

Operating lease liability, net of current portion
13,729 13,829
Deferred tax liabilities
823 -
Total liabilities
36,724 25,255

Commitments and contingencies

Shareholders' Equity
Common stock at par value
176 171
Additional paid-in capital
787,856 772,221
Accumulated other comprehensive loss
57 (127)
Accumulated deficit
(701,551) (682,524)
Total shareholders' equity
86,538 89,741
Total liabilities and shareholders' equity
$123,262 $114,996


MicroVision, Inc.
Consolidated Statement of Operations
(In thousands, except earnings per share data)
(Unaudited)

Three months ended March 31,

2023 2022






Revenue
$782 $350

Cost of revenue
544 4

Gross profit
238 346


Research and development expense
12,692 7,593
Sales, marketing, general and administrative expense
8,737 5,877
Total operating expenses
21,429 13,470

Loss from operations
(21,191) (13,124)

Bargain purchase gain, net of tax
1,706 -
Other income (expense), net
639 (44)

Net loss before taxes
$(18,846) $(13,168)

Income tax expense
(181) -

Net income (loss)
$(19,027) $(13,168)

Net income (loss) per share - basic and diluted
$(0.11) $(0.08)

Weighted-average shares outstanding - basic and diluted
174,703 164,563

MicroVision, Inc.
Consolidated Statement of Cash Flows
(In thousands)
(Unaudited)


Three months ended March 31,


2023 2022



Cash flows from operating activities


Net loss
$(19,027) $(13,168)
Adjustments to reconcile net loss to net cash used in operations:
Depreciation and amortization
2,271 483
Bargain purchase gain, net of tax
1,706 -
Impairment of property and equipment
- 60
Share-based compensation expense
2,949 3,734
Inventory write-downs
29 -
Net accretion of premium on short-term investments
(396) 160
Change in
Accounts receivable
(506) -
Contract assets
(192) -
Inventory
(87) (35)
Other current and non-current assets
647 389
Accounts payable
1,629 (1,292)
Accrued liabilities
(2,367) 118
Contract liabilities and other current liabilities
195 (1,057)
Operating lease liabilities
(669) (299)
Other clong-term liabilities
17 -
Net cash used in operating activities
(13,801) (10,907)

Cash flows from investing activities
Sales of investment securities
22,000 1,500
Purchases of investment securities
(3,898) (16,696)
Acquisition of Ibeo assets
(10,914) -
Purchases of property and equipment
(615) (884)
Net cash provided by (used in) investing activities
6,573 (16,080)

Cash flows from financing activities
Principal payments under finance leases
(6) (8)
Principal payments under long-term debt
- (294)
Proceeds from stock option exercises
- 253
Net proceeds from issuance of common stock
12,691 -
Net cash provided by financing activities
12,685 (49)

Change in cash, cash equivalents, and restricted cash
5,457 (27,036)
Cash, cash equivalents and restricted cash at beginning of period
21,954 83,739
Cash, cash equivalents and restricted cash at end of period
$27,411 $56,703



The following table provides a reconciliation of the cash, cash equivalents, and restricted cash balances as of
March 31, 2023 and December 31, 2022:

March 31,December 31,

2023 2022
Cash and cash equivalents
$23,187 $20,536
Restricted cash
4,224 1,418
Cash, cash equivalents and restricted cash
27,411 21,954

MicroVision, Inc.
Reconciliation of GAAP to Non-GAAP Measures
(In thousands, except earnings per share data)
(Unaudited)


Three months ended March 31,


2023 2022



Reconciliation of Non-GAAP Gross Profit:


Gross Profit
$238 $346
Share-based compensation expense
- -
Amortization of acquired intangibles
255 -
Non-GAAP Gross Profit
$493 $346

Reconciliation of GAAP Net Loss to Non-GAAP Measure:
GAAP net loss
$(19,027) $(13,168)
Add Interest (net)
(499) (31)
Add Income taxes
181 -
Add Depreciation & amorization
2,271 483
Add Bargain purchase gain
(1,706) -
Add Share-based compensation expense
2,949 3,734
Adjusted EBITDA
$(15,831) $(8,982)

SOURCE: MicroVision, Inc.



View source version on accesswire.com:
https://www.accesswire.com/753823/MicroVision-Announces-First-Quarter-2023-Results

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

Chervon Launches Advanced Momentum Program (AMP) to Hire & Develop the Next Generation of Leaders30.10.2026 14:00:00 CET | Press release

NAPERVILLE, IL / ACCESS Newswire / October 30, 2026 / Chervon launches Advanced Momentum Program (AMP), reporting to Matt DeFeo, Senior Vice President, Sales, Training, and Recruiting. Chervon will be hiring hundreds of college graduates in the months and years ahead to deliver the company's aggressive growth strategy. The new AMP initiative was developed to catalyze Chervon's recruiting, training, development, promoting, and mentoring of the very best high-potential college grads. AMP will develop the next generation of Chervon leaders. The program features a comprehensive product, skills, and career development training system. AMP will recruit, develop and promote high-potential new hires into a broad range of positions including store coverage, end-user marketing, sales, product management, e-commerce/digital marketing, channel management, commercialization, service, engineering, supply chain, operations, and finance. Ultimately AMP will produce a stream of outstanding senior execu

Aehr Test Systems Appoints Former Meta Infrastructure Executive Vijay Rao to Board of Directors29.10.2026 12:30:00 CET | Press release

FREMONT, CA / ACCESS Newswire / October 29, 2026 / Aehr Test Systems (NASDAQ:AEHR), a leading provider of test and burn-in solutions for semiconductor devices used in artificial intelligence (AI), silicon photonics, data center, automotive, and industrial applications, today announced the appointment of Vijay Rao to its Board of Directors, effective October 28, 2026. Rao brings 30 years of technology industry experience, including more than 13 years at Meta, where he most recently served as Vice President of Infrastructure. His experience spans infrastructure strategy, AI computing, and semiconductor technologies in hyperscale, enterprise, and startup environments. "Vijay brings deep expertise in infrastructure requirements of hyperscale data centers, including the integration of AI accelerators, high-performance memory, and optical networking," said Gayn Erickson, President and Chief Executive Officer of Aehr Test Systems. "He understands firsthand how semiconductor quality and reliab

U.S. Polo Assn. Executes Early on Europe's Digital Product Passport Mandate29.10.2026 12:00:00 CET | Press release

WEST PALM BEACH, FL / ACCESS Newswire / October 29, 2026 / U.S. Polo Assn.®, the official sports brand of the United States Polo Association (USPA), with a multi-billion-dollar global footprint and distribution in more than 190 countries through some 1,200 U.S. Polo Assn. mono-brand retail stores, numerous branded websites and thousands of other points of distribution worldwide, today announced the brand's early activation of Digital Product Passports (DPPs) across product categories sold into the European Union (EU). As Europe prepares to launch the Digital Product Passport Registry, U.S. Polo Assn. has taken a proactive approach by preparing to deploy DPPs across all products sold into the EU well ahead of the mandatory compliance deadline expected in 2028 or 2029. The global sports brand has already mapped product information for millions of products, creating a scalable framework that will enhance product transparency and support compliance readiness throughout its European operati

LiberNovo Previews Treat Yourself Halloween Flash Sale Across Europe29.10.2026 08:40:00 CET | Press release

HONG KONG, HK / ACCESS Newswire / October 29, 2026 / LiberNovo is bringing Halloween treats to the desk with its Treat Yourself Halloween Flash Sale, opening October 29 across the European Union and United Kingdom. The event pairs savings of up to 40% on selected Maxis and LiberNovo Omni Pro configurations with limited seasonal gifts for qualifying early shoppers. Spooky extras for your desk Limited Halloween-themed gift packs are available to the first 300 eligible customers in the European Union and the first 100 in the United Kingdom, on a first-come, first-served basis while supplies last. Gift contents, qualifying purchases and availability follow the terms on each regional campaign page. More room for Big and Tall users Maxis is designed around larger frames, with a wider seat and 52 cm seat depth for greater thigh support and room to shift naturally. Maxis Manual provides adjustment by hand. Maxis Electric adds motorised lumbar adjustment and OmniStretch guided back stretching.

IAVI Awarded $36 Million From BARDA for Bundibugyo Virus Vaccine Development28.10.2026 16:50:00 CET | Press release

NEW YORK, NY, SINGAPORE, SG INCHEON, SOUTH KOREA, AND DESSAU-ROSSLAU, DE / ACCESS Newswire / October 28, 2026 / Today IAVI, a global nonprofit biomedical research organization, together with partners Hilleman Laboratories, SK bioscience, and IDT Biologika announced that IAVI has been awarded US $36 million of a contract valued up to US $99 million from the Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services, to advance development, manufacturing, and clinical evaluation of its one-dose vaccine candidate against Bundibugyo virus (BDBV), the cause of the ongoing Ebola epidemic in the Democratic Republic of the Congo (DRC). The award supports manufacturing of vaccine doses for clinical evaluation and outbreak response, clinical and regulatory activities including a Phase 1 trial, and options for expanded manufacturing to support future preparedness needs, as

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye